Needham Maintains Buy on Veracyte, Raises Price Target to $57

Benzinga Newsdesk www.benzinga.com Positive 67.3%

Neg 0% Neu 0% Pos 67.3%

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $48 to $57.

Comments

No comments yet. Be the first!